Our group identified 61 patients with advanced or metastatic CCA, 19 males (31%) and 42 females (69%), harboring FGFR alterations who received FGFRi….Median progression-free survival on FGFRi was 5.8 months for all patients (95% CI, 4.9 to 9.0). Median OS from time of FGFRi initiation for patients with FGFR2 fusion or rearrangement was 20.2 months (95% CI, 11.8 to 38.3) compared to patients with other FGFR alterations at 13.0 months....FGFRi are well tolerated with clinical efficacy.